Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High-Dose ICS in Children With Uncontrolled Moderate-to-Severe Type 2 Asthma.
Leonard B Bacharier, Jorge F Maspero, Nikolaos G Papadopoulos, Rémi Gagnon, Theresa W Guilbert, Changming Xia, Olivier Ledanois, Mena Soliman
BACKGROUND: Dupilumab improved clinical outcomes in children (aged 6-11 years) with moderate-to-severe asthma and type 2 inflammation (baseline blood eosinophil count ≥ 150 cells/μL or fractional exhaled nitric oxide [FeNO] ≥ 20 ppb) in the phase 3 VOYAGE study (NCT02948959). We evaluated dupilumab plus medium-dose ICS versus placebo plus continued high-dose ICS in children in VOYAGE.
METHODS: Children were randomized to dupilumab 100/200 mg by body weight or placebo every 2 weeks for 52 weeks. Annualized severe exacerbation rates, change from baseline in pre-bronchodilator percent predicted forced expiratory volume in 1 s (ppFEV1), morning peak expiratory flow (PEF), 7-item Asthma Control Questionnaire-Investigator Administered (ACQ-7-IA) score, FeNO, blood eosinophil count, and total IgE at Week 52 were assessed.
RESULTS: Data from 184 children were analyzed (dupilumab plus medium-dose ICS, n = 134; placebo plus high-dose ICS, n = 50). At Week 52, dupilumab plus medium-dose ICS versus placebo plus high-dose ICS significantly reduced exacerbations by 74.3%, and significantly improved ppFEV1, morning PEF, ACQ-7-IA score, FeNO, and total IgE. There was no significant difference in blood eosinophil counts between the two groups.
CONCLUSION: In children with moderate-to-severe asthma and type 2 inflammation, treatment with dupilumab plus medium-dose ICS reduced exacerbations and improved lung function and asthma control compared with placebo plus continued high-dose ICS.
KM 提取结果
0 个 Figure · 0 个 KM 面板
尚未提取到 KM 面板。其他 Figure(4,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。
Figure 1Figure 1 Reduction in severe asthma exacerbation rates a at VOYAGE Week 52 in children with moderate‐to‐severe asthma who received dupilumab plus medium‐dose ICS or placebo plus high‐dose ICS. a Derived using a negative binomial model with the total number of event onsets from randomization up to Week 52 visit or last contact date (whichever comes earlier) as the response variable, the treatment group, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, and number of severe exacerbations within 1 year before the study as covariates, and log‐transformed standardized observation duration as an offset variable. CI, confidence interval; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; q2w, every 2 weeks; SD, standard deviation. *** p < 0.0001 versus matched placebo. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
Figure 2Figure 2 Change from baseline to Week 52 in (A) pre‐bronchodilator ppFEV 1 a (percentage points) and (B) morning PEF b (L/min) in children from VOYAGE who received dupilumab plus medium‐dose ICS or placebo plus high‐dose ICS. a Derived from an MMRM with change from baseline in pre‐bronchodilator ppFEV 1 values up to Week 52 as the response variable, and treatment, baseline weight group, region, ethnicity, baseline eosinophil level, baseline FeNO level, visit, treatment‐by‐visit interaction, baseline ppFEV 1 value, and baseline‐by‐visit interaction as covariates. b Derived from an MMRM with change from baseline in morning PEF (L/min) values up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, visit, treatment‐by‐visit interaction, baseline morning PEF (L/min) value, and baseline‐by‐visit interaction as covariates. FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; LS, least squares; MMRM, mixed‐effect model with repeated measures; PEF, peak expiratory flow; ppFEV 1 , percent predicted forced expiratory volume in 1 second; q2w, every 2 weeks; SE, standard error. * p < 0.05, ** p < 0.01, *** p < 0.0001 versus matched placebo. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
Figure 3Figure 3 Change from baseline to Week 52 in ACQ‐7‐IA score a over time in children from VOYAGE who received dupilumab plus medium‐dose ICS or placebo plus high‐dose ICS. a Derived from an MMRM with change from baseline in ACQ‐7‐IA up to Week 52 as the response variable, and treatment, age, baseline weight group, region, baseline eosinophil level, baseline FeNO level, visit, treatment‐by‐visit interaction, baseline ACQ‐7‐IA, and baseline‐by‐visit interaction as covariates. ACQ‐7‐IA, 7‐item Asthma Control Questionnaire‐Investigator Administered; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; LS, least squares; MMRM, mixed‐effect model with repeated measures; q2w, every 2 weeks; SE, standard error. * p < 0.05, ** p < 0.01, *** p < 0.0001 versus matched placebo. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
Figure 4Figure 4 Change from baseline to Week 52 in (A) FeNO a (ppb), (B) blood eosinophil count b (cells/µL), and (C) serum total IgE b (IU/mL) in children from VOYAGE who received dupilumab plus medium‐dose ICS or placebo plus high‐dose ICS. a Derived from an MMRM with change from baseline in FeNO up to Week 52 as the response variable, and pooled treatment group, age, baseline weight group (≤ 30 kg, > 30 kg), region, baseline eosinophil strata (< 150 cells/µL, ≥ 150 cells/µL), visit, treatment by‐visit interaction, baseline FeNO value, and baseline‐by‐visit interaction as covariates. b Based on a rank ANCOVA model adjusted for baseline values, age, baseline weight group (≤ 30 kg, > 30 kg), region, and baseline FeNO levels (< 20 ppb, ≥ 20 ppb), comparing dupilumab plus medium‐dose ICS with placebo plus high‐dose ICS. The analysis of changes in total IgE was also adjusted for baseline blood eosinophil strata (< 150 cells/µL, ≥ 150 cells/µL). Three patients were excluded due to missing baseline FeNO levels. ANCOVA, analysis of covariance; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; IgE, immunoglobulin E; IU, International Units; MMRM, mixed‐effect model with repeated measures; ppb; parts per billion; Q, quartile; q2w, every 2 weeks; SE, standard error. *** p < 0.0001 versus matched placebo. [Color figure can be viewed at wileyonlinelibrary.com ]